Your browser is no longer supported. Please, upgrade your browser.
ADRO Aduro Biotech, Inc. weekly Stock Chart
Aduro Biotech, Inc.
Index- P/E- EPS (ttm)-0.80 Insider Own0.80% Shs Outstand80.86M Perf Week16.95%
Market Cap224.55M Forward P/E- EPS next Y-0.65 Insider Trans-9.29% Shs Float56.97M Perf Month-8.61%
Income-64.60M PEG- EPS next Q-0.16 Inst Own56.30% Short Float5.79% Perf Quarter15.97%
Sales28.00M P/S8.02 EPS this Y15.00% Inst Trans4.86% Short Ratio6.21 Perf Half Y10.40%
Book/sh0.58 P/B4.76 EPS next Y-19.30% ROA-22.30% Target Price3.75 Perf Year126.23%
Cash/sh2.10 P/C1.31 EPS next 5Y9.00% ROE-101.70% 52W Range0.90 - 4.04 Perf YTD133.90%
Dividend- P/FCF- EPS past 5Y-30.40% ROI-133.70% 52W High-31.68% Beta0.38
Dividend %- Quick Ratio8.90 Sales past 5Y5.20% Gross Margin- 52W Low206.29% ATR0.21
Employees96 Current Ratio8.90 Sales Q/Q14.30% Oper. Margin- RSI (14)52.89 Volatility7.56% 7.20%
OptionableYes Debt/Eq0.00 EPS Q/Q11.50% Profit Margin- Rel Volume2.49 Prev Close2.49
ShortableYes LT Debt/Eq0.00 EarningsAug 03 BMO Payout- Avg Volume530.93K Price2.76
Recom2.70 SMA200.33% SMA500.89% SMA20012.00% Volume1,322,470 Change10.84%
Jan-10-20Downgrade Cowen Outperform → Market Perform
Dec-18-19Downgrade William Blair Outperform → Mkt Perform
Jun-03-19Downgrade Oppenheimer Outperform → Perform
Apr-15-19Initiated SVB Leerink Outperform $9
Feb-22-18Initiated Cantor Fitzgerald Overweight $15
Dec-13-17Reiterated H.C. Wainwright Buy $18 → $9.50
May-01-17Initiated Rodman & Renshaw Buy $18
May-17-16Reiterated FBR Capital Outperform $30 → $22
Mar-15-16Downgrade BofA/Merrill Buy → Underperform $32 → $14
Mar-02-16Initiated FBR Capital Outperform $30
Dec-01-15Downgrade Oppenheimer Outperform → Perform
Nov-24-15Reiterated ROTH Capital Buy $74 → $68
Oct-20-15Initiated Oppenheimer Outperform $30
May-11-15Initiated Leerink Partners Outperform $48
May-11-15Initiated Canaccord Genuity Buy $43
May-11-15Initiated BofA/Merrill Buy $40
Apr-20-15Initiated ROTH Capital Buy $74
Aug-03-20 07:15PM  
Jul-04-20 03:38PM  
Jun-24-20 08:15AM  
Jun-18-20 09:00AM  
Jun-02-20 10:41AM  
May-26-20 08:11AM  
May-25-20 12:00PM  
May-19-20 08:15AM  
May-11-20 08:35AM  
May-10-20 08:07AM  
May-06-20 06:12AM  
May-04-20 07:35PM  
Apr-28-20 12:34PM  
Apr-17-20 11:30AM  
Apr-12-20 08:33AM  
Apr-08-20 11:30AM  
Apr-03-20 05:50PM  
Apr-01-20 11:30AM  
Mar-23-20 05:50PM  
Mar-16-20 11:30AM  
Mar-11-20 02:20PM  
Mar-09-20 05:55PM  
Mar-05-20 05:50PM  
Feb-28-20 11:30AM  
Feb-24-20 04:15PM  
Feb-19-20 12:31PM  
Feb-06-20 04:15PM  
Jan-10-20 06:03PM  
Jan-09-20 04:15PM  
Dec-14-19 05:18PM  
Dec-09-19 05:06AM  
Dec-07-19 11:31AM  
Nov-08-19 04:05PM  
Nov-07-19 07:35PM  
Oct-25-19 07:49AM  
Oct-02-19 04:05PM  
Sep-30-19 04:05PM  
Sep-19-19 09:49AM  
Sep-04-19 08:30AM  
Sep-03-19 04:05PM  
Aug-31-19 09:31AM  
Aug-14-19 02:32PM  
Aug-05-19 10:46AM  
Aug-01-19 04:05PM  
Jul-31-19 10:36AM  
Jul-16-19 11:04AM  
Jun-04-19 10:32AM  
Jun-02-19 11:45AM  
May-20-19 04:53PM  
May-15-19 05:06PM  
May-08-19 12:06PM  
May-07-19 06:45PM  
May-06-19 04:13PM  
May-03-19 05:22PM  
May-02-19 10:58AM  
May-01-19 06:07PM  
Apr-30-19 11:39AM  
Apr-29-19 06:14PM  
Apr-28-19 11:52PM  
Apr-26-19 11:48AM  
Apr-25-19 11:55AM  
Apr-24-19 04:32PM  
Apr-22-19 11:08AM  
Apr-18-19 04:05PM  
Apr-17-19 04:05PM  
Apr-08-19 08:47AM  
Apr-01-19 08:00AM  
Aduro Biotech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase II clinical trial in combination with pembrolizumab, an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and natural killer cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; and license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro Biotech, Inc. in June 2008. Aduro Biotech, Inc. was founded in 2000 and is headquartered in Berkeley, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ISAACS STEPHEN TPresident and CEOSep 15Sale2.3932,48177,691279,166Sep 17 08:17 PM
Templeman BlaineChief Legal OfficerSep 15Sale2.3912,36929,585121,916Sep 17 08:16 PM
Ferber CelesteSVP, GC and SecretarySep 15Sale2.392,3965,73138,687Sep 17 08:15 PM
Nuyten Dimitry SAChief Medical OfficerAug 07Sale2.553,5389,0368,462Aug 11 04:06 PM
Templeman BlaineChief Legal OfficerAug 07Sale2.557,95120,308134,285Aug 11 04:05 PM
Ferber CelesteSVP, GC and SecretaryAug 07Sale2.557,95120,30841,083Aug 11 04:04 PM
Greenman William MarinerDirectorMar 18Option Exercise0.4519,8358,92619,835Mar 20 05:18 PM
van Elsas AndreaChief Scientific OfficerFeb 25Sale3.516,82323,954438,367Feb 26 06:58 PM
van Elsas AndreaChief Scientific OfficerJan 03Sale1.1973,31187,108445,190Jan 06 06:38 PM
Templeman BlaineChief Legal OfficerDec 12Sale1.161,2641,470117,736Dec 16 04:14 PM
van Elsas AndreaChief Scientific OfficerDec 12Sale1.162,1922,550518,501Dec 16 04:13 PM
Ferber CelesteSVP, GC and SecretaryDec 12Sale1.1640847526,534Dec 16 04:13 PM
ISAACS STEPHEN TPresident and CEODec 12Sale1.165,8976,860290,029Dec 16 04:12 PM